Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...
A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...
Up to 28.7% weight loss in a 68-week late-stage trial * Reduced knee osteoarthritis pain by up to 62.6% * First ...
Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...
LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback